

IN THE CLAIMS:

For the convenience of the Examiner a clean copy of all pending claims is provided below:

15. (Amended) A method of inducing apoptosis in a cell comprising administering to said cell an apoptosis inducing substance selected from the group consisting of:

- an isolated or recombinant nucleic acid of SEQ ID NO 1 or SEQ ID NO 9,
- a vector comprising an isolated or recombinant nucleic acid of SEQ ID NO 1 or SEQ ID NO 9,
- a host cell transformed with an isolated or recombinant nucleic acid of SEQ ID NO 1 or SEQ ID NO 9, and
- mixtures thereof.

16. (Amended) The method according to claim 15 wherein said apoptosis inducing substance is administered to a p53-minus cell.

19. (Amended) A method for treating a subject having a disease wherein enhanced cell proliferation or decreased cell death is observed, said method comprising treating the subject with the pharmaceutical composition comprising:

a pharmaceutically acceptable amount of a component selected from the group consisting of:

- an isolated or recombinant nucleic acid of SEQ ID NO 1 or SEQ ID NO 9,
- a vector comprising an isolated or recombinant nucleic acid of SEQ ID NO 1 or SEQ ID NO 9,
- a host cell transformed with an isolated or recombinant nucleic acid of SEQ ID NO 1 or SEQ ID NO 9, and
- mixtures thereof,

together with a pharmaceutically acceptable carrier, acceptable for said subject and said component to induce apoptosis.

20. The method according to claim 19 wherein said disease comprises cancer or autoimmune disease.

21. (Amended) The method according to claim 19 wherein said apoptosis inducing substance is administered to a p53-minus cell.